Showing results (281-290 of 1,343) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|October 19, 2019
Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic reviewFrank Eektimmerman, Jesse J Swen, Moenira B Madhar, et al.
The Pharmacogenomics Journal|October 19, 2019
Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancerQianqian Meng, Shuyuan Wang, Shunheng Zhou, et al.
The Pharmacogenomics Journal|April 2, 2022
Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysisShangqing Jiang, Patrick C Mathias, Nathaniel Hendrix, et al.
The Pharmacogenomics Journal|October 18, 2019
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patientsJessica Cusato, Andrea Calcagno, Letizia Marinaro, et al.
The Pharmacogenomics Journal|December 10, 2009
A multistep validation process of biomarkers for preclinical drug developmentW M Freeman, G V Bixler, R M Brucklacher, et al.
The Pharmacogenomics Journal|September 26, 2018
Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysisQian Xiang, Shu-Qing Chen, Ling-Yue Ma, et al.
The Pharmacogenomics Journal|April 4, 2023
One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyStefania Cheli, Diego Savino, Annalisa De Silvestri, et al.
The Pharmacogenomics Journal|August 22, 2012
Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorderF W Lohoff, S Narasimhan, K Rickels
The Pharmacogenomics Journal|July 20, 2020
Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data?Catherine J E Ingram, Rosemary Ekong, Naser Ansari-Pour, et al.
The Pharmacogenomics Journal|June 27, 2012
Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6N González-Vacarezza, F Abad-Santos, A Carcas-Sansuan, et al.
Pageof 135